AIRS · AirSculpt Technologies, Inc.

AirSculpt Technologies reported challenging full year 2025 results, with revenue declining 15.8% to $151.8 million and case volume falling 15.6% to 11,852 procedures. The company faced headwinds from increased competition in the weight loss and obesity solutions market, specifically citing regulatory approval and market acceptance of weight-loss drugs. Despite the revenue decline, the fourth quarter showed operational improvement with Adjusted EBITDA increasing to $2.5 million from $1.9 million in the prior year period, and the company achieved a net income of $1.3 million compared to a $5.0 million loss in Q4 2024. Management attributed sequential improvements to strategic initiatives implemented during 2025, including talent additions, process improvements, and a new go-to-market strategy. CEO Yogi Jashnani highlighted that same-store sales turned positive in February 2026, signaling potential stabilization. The company strengthened its balance sheet in early 2026, raising $14.8 million through an at-the-market offering and reducing gross debt from approximately $56.0 million to $45.0 million. Looking ahead, management provided 2026 guidance projecting revenue of $151 to $157 million and Adjusted EBITDA of $15 to $17 million, implying a recovery in profitability metrics. The company also announced a change in its Annual Meeting of Stockholders date to May 12, 2026.